Browse ZBTB46

Summary
SymbolZBTB46
Namezinc finger and BTB domain containing 46
Aliases FLJ13502; BZEL; BTB-ZF protein expressed in effector lymphocytes; ZNF340; BTBD4; BTB (POZ) domain containing ......
Chromosomal Location20q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF00651 BTB/POZ domain
Function

Function as a transcriptional repressor for PRDM1.

> Gene Ontology
 
Biological Process GO:0002521 leukocyte differentiation
GO:0002573 myeloid leukocyte differentiation
GO:0002683 negative regulation of immune system process
GO:0002761 regulation of myeloid leukocyte differentiation
GO:0002762 negative regulation of myeloid leukocyte differentiation
GO:0030099 myeloid cell differentiation
GO:0030224 monocyte differentiation
GO:0030225 macrophage differentiation
GO:0030851 granulocyte differentiation
GO:0030852 regulation of granulocyte differentiation
GO:0030853 negative regulation of granulocyte differentiation
GO:0045637 regulation of myeloid cell differentiation
GO:0045638 negative regulation of myeloid cell differentiation
GO:0045649 regulation of macrophage differentiation
GO:0045650 negative regulation of macrophage differentiation
GO:0045655 regulation of monocyte differentiation
GO:0045656 negative regulation of monocyte differentiation
GO:0097028 dendritic cell differentiation
GO:1902105 regulation of leukocyte differentiation
GO:1902106 negative regulation of leukocyte differentiation
GO:1902107 positive regulation of leukocyte differentiation
GO:1903131 mononuclear cell differentiation
GO:1903706 regulation of hemopoiesis
GO:1903707 negative regulation of hemopoiesis
GO:1903708 positive regulation of hemopoiesis
GO:2001198 regulation of dendritic cell differentiation
GO:2001199 negative regulation of dendritic cell differentiation
GO:2001200 positive regulation of dendritic cell differentiation
Molecular Function -
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolZBTB46
Namezinc finger and BTB domain containing 46
Aliases FLJ13502; BZEL; BTB-ZF protein expressed in effector lymphocytes; ZNF340; BTBD4; BTB (POZ) domain containing ......
Chromosomal Location20q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ZBTB46 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between ZBTB46 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
25446897MelanomaPromote immunityWithin these, CD103(+) DCs are extremely sparse and yet remarkably capable CTL stimulators. These are uniquely dependent on IRF8, Zbtb46, and Batf3 transcription factors and are generated by GM-CSF and FLT3L cytokines. Regressing tumors have higher proportions of these cells, T-cell-dependent immune clearance relies on them, and abundance of their transcripts in human tumors correlates with clinical outcome.
Summary
SymbolZBTB46
Namezinc finger and BTB domain containing 46
Aliases FLJ13502; BZEL; BTB-ZF protein expressed in effector lymphocytes; ZNF340; BTBD4; BTB (POZ) domain containing ......
Chromosomal Location20q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ZBTB46 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolZBTB46
Namezinc finger and BTB domain containing 46
Aliases FLJ13502; BZEL; BTB-ZF protein expressed in effector lymphocytes; ZNF340; BTBD4; BTB (POZ) domain containing ......
Chromosomal Location20q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ZBTB46 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.2810.331
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.3530.641
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2330.721
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0640.874
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.5860.746
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.5980.8
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.4340.228
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.4660.577
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.4280.63
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.4320.608
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.1960.27
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2280.0759
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ZBTB46 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.3014.30.238
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131123.1023.10.223
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolZBTB46
Namezinc finger and BTB domain containing 46
Aliases FLJ13502; BZEL; BTB-ZF protein expressed in effector lymphocytes; ZNF340; BTBD4; BTB (POZ) domain containing ......
Chromosomal Location20q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ZBTB46. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolZBTB46
Namezinc finger and BTB domain containing 46
Aliases FLJ13502; BZEL; BTB-ZF protein expressed in effector lymphocytes; ZNF340; BTBD4; BTB (POZ) domain containing ......
Chromosomal Location20q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ZBTB46. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ZBTB46.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolZBTB46
Namezinc finger and BTB domain containing 46
Aliases FLJ13502; BZEL; BTB-ZF protein expressed in effector lymphocytes; ZNF340; BTBD4; BTB (POZ) domain containing ......
Chromosomal Location20q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ZBTB46. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolZBTB46
Namezinc finger and BTB domain containing 46
Aliases FLJ13502; BZEL; BTB-ZF protein expressed in effector lymphocytes; ZNF340; BTBD4; BTB (POZ) domain containing ......
Chromosomal Location20q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ZBTB46 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolZBTB46
Namezinc finger and BTB domain containing 46
Aliases FLJ13502; BZEL; BTB-ZF protein expressed in effector lymphocytes; ZNF340; BTBD4; BTB (POZ) domain containing ......
Chromosomal Location20q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ZBTB46 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolZBTB46
Namezinc finger and BTB domain containing 46
Aliases FLJ13502; BZEL; BTB-ZF protein expressed in effector lymphocytes; ZNF340; BTBD4; BTB (POZ) domain containing ......
Chromosomal Location20q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ZBTB46 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.